These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29204855)

  • 1. Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden.
    Jendle J; Ericsson Å; Hunt B; Valentine WJ; Pollock RF
    Diabetes Ther; 2018 Feb; 9(1):87-99. PubMed ID: 29204855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis.
    Jendle J; Ericsson Å; Gundgaard J; Møller JB; Valentine WJ; Hunt B
    Diabetes Ther; 2021 Jan; 12(1):373-388. PubMed ID: 33306169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden.
    Jendle J; Buompensiere MI; Holm AL; de Portu S; Malkin SJP; Cohen O
    Diabetes Ther; 2021 Nov; 12(11):2977-2991. PubMed ID: 34596879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
    Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
    Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
    Jendle J; Ericsson Å; Ekman B; Sjöberg S; Gundgaard J; da Rocha Fernandes J; Mårdby AC; Hunt B; Malkin SJP; Thunander M
    J Med Econ; 2020 Nov; 23(11):1311-1320. PubMed ID: 32746676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioural interventions for type 2 diabetes: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(21):1-45. PubMed ID: 23074526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
    Salas M; Ward A; Caro J
    Clin Ther; 2002 Oct; 24(10):1690-705. PubMed ID: 12462297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets.
    Valentine WJ; Palmer AJ; Nicklasson L; Cobden D; Roze S
    Int J Clin Pract; 2006 Sep; 60(9):1138-45. PubMed ID: 16939559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden.
    Jendle J; Smith-Palmer J; Delbaere A; de Portu S; Papo N; Valentine W; Roze S
    Diabetes Ther; 2017 Oct; 8(5):1015-1030. PubMed ID: 28871565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
    Valentine WJ; Palmer AJ; Lammert M; Nicklasson L; Foos V; Roze S
    Curr Med Res Opin; 2005 Dec; 21(12):2063-71. PubMed ID: 16368057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
    Palmer JL; Goodall G; Nielsen S; Kotchie RW; Valentine WJ; Palmer AJ; Roze S
    Curr Med Res Opin; 2008 May; 24(5):1417-28. PubMed ID: 18400145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.
    Brändle M; Erny-Albrecht KM; Goodall G; Spinas GA; Streit P; Valentine WJ
    Int J Clin Pharmacol Ther; 2009 Aug; 47(8):501-15. PubMed ID: 19640359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structured, intensive education maximising engagement, motivation and long-term change for children and young people with diabetes: a cluster randomised controlled trial with integral process and economic evaluation - the CASCADE study.
    Christie D; Thompson R; Sawtell M; Allen E; Cairns J; Smith F; Jamieson E; Hargreaves K; Ingold A; Brooks L; Wiggins M; Oliver S; Jones R; Elbourne D; Santos A; Wong IC; O'Neill S; Strange V; Hindmarsh P; Annan F; Viner R
    Health Technol Assess; 2014 Mar; 18(20):1-202. PubMed ID: 24690402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.
    Goodall G; Jendle JH; Valentine WJ; Munro V; Brandt AB; Ray JA; Roze S; Foos V; Palmer AJ
    Int J Clin Pract; 2008 Jun; 62(6):869-76. PubMed ID: 18479280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.